2025 North America Alzheimer'S Disease Diagnostic Market Revenue Opportunities Report
Description
The 2025 North America Alzheimer'S Disease Diagnostic Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Alzheimer's Disease Diagnostic Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Alzheimer's disease diagnostic market in North America include Quest Diagnostics, Labcorp, F. Hoffmann-La Roche (Roche), and Fujirebio. Quest Diagnostics recently launched the AD-Detect Test, a blood-based biomarker test assessing beta-amyloid proteins, a key Alzheimer's indicator, enhancing risk assessment capabilities for consumers in the U.S. Labcorp similarly offers advanced diagnostic testing services in the region. Roche is notable for its collaboration with ALZpath, utilizing the pTau217 antibody for highly sensitive blood-based detection, with their assay receiving FDA breakthrough device designation. Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio test also gained FDA approval in 2025 for early amyloid plaque detection in adults showing symptoms.
These companies lead due to significant investments in R&D, leveraging technological advances in blood biomarker tests and imaging techniques such as PET and MRI. The presence of an aging population with increasing Alzheimer's prevalence, combined with robust healthcare infrastructure and supportive government funding, underpins North America's market dominance, holding approximately 40-48% market share. Innovation efforts focus on early detection to enable timely treatment and monitoring, with collaborations between diagnostics, pharmaceutical firms, and research institutes intensifying to develop more accurate, accessible, and non-invasive diagnostic tools for Alzheimer’s disease.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Alzheimer's Disease Diagnostic Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Alzheimer's disease diagnostic market in North America include Quest Diagnostics, Labcorp, F. Hoffmann-La Roche (Roche), and Fujirebio. Quest Diagnostics recently launched the AD-Detect Test, a blood-based biomarker test assessing beta-amyloid proteins, a key Alzheimer's indicator, enhancing risk assessment capabilities for consumers in the U.S. Labcorp similarly offers advanced diagnostic testing services in the region. Roche is notable for its collaboration with ALZpath, utilizing the pTau217 antibody for highly sensitive blood-based detection, with their assay receiving FDA breakthrough device designation. Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio test also gained FDA approval in 2025 for early amyloid plaque detection in adults showing symptoms.
These companies lead due to significant investments in R&D, leveraging technological advances in blood biomarker tests and imaging techniques such as PET and MRI. The presence of an aging population with increasing Alzheimer's prevalence, combined with robust healthcare infrastructure and supportive government funding, underpins North America's market dominance, holding approximately 40-48% market share. Innovation efforts focus on early detection to enable timely treatment and monitoring, with collaborations between diagnostics, pharmaceutical firms, and research institutes intensifying to develop more accurate, accessible, and non-invasive diagnostic tools for Alzheimer’s disease.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
